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Gelatinase A is a glomerular mesangial cell growth and
differentiation factor
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Gelatinase A is a glomerular mesangial cell growth and differentiation
factor. The members of the matrix metalloproteinase gene family play
critical roles in numerous physiologic events, including cellular migration,
tissue remodeling in wound healing and development, as well as in the
evolution of the inflammatory process. The 72 kDa gelatinase A (formerly
denoted 72 kDa Type IV collagenase) is centrally involved in the
inflammatory and sclerotic events common to most forms of chronic
glomerular disease. In this article recent studies are summarized which
demonstrate that this particular enzyme can directly affect the prolifera-
tive and differentiation properties of the intrinsic glomerular mesangial
cell, both in vitro and in vivo.
Progressive glomeruloscierosis leading to end-stage renal fail-
ure is a unifying feature of most forms of chronic glomerular
disease. An extensive body of literature has documented the
central role of the intrinsic mesangial cell in the complex biologic
events that characterize the sclerotic process. Our laboratory has
focused on the role of a specific matrix metalloproteinase, the 72
kDa gelatinase A (also denoted matrix metalloproteinase 2,
MMP-2) in the evolution of glomerular injury [1—3]. While
normally quiescent and non-proliferative, during inflammatory
states and in culture the mesangial cell acquires a characteristic
spectrum of features that may be defined as the "inflammatory
phenotype." These features include rapid proliferative rates,
expression of new proteins such as a-smooth muscle actin, and
enhanced synthesis of extracellular matrix proteins [4]. The
acquisition of this inflammatory phenotype is directly coupled
with high level synthesis of gelatinase A. The fundamental hy-
pothesis of our studies is that persistent mesangial synthesis of
gelatinase A is a common feature of the response to inflammatory
injury that directly mediates the evolution to the sclerotic state. In
this article we summarize some recent findings [5] concerning the
proliferative and differentiation-specific effects of gelatinase A on
glomerular mesangial cells, and discuss some of the potential
mechanisms of action of this unusual member of the matrix
metalloproteinase gene family.
Evidence for a regulatory role of gelatinase A in the control of
mesangial cell proliferation and differentiation
Many aspects of the in vivo inflammatory phenotype, including
high level gelatinase A synthesis, are simulated by cultured MC.
To evaluate the significance of gelatinase A secretion for the
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acquisition of the inflammatory phenotype, a line of MC was
developed by single cell cloning that constitutively expressed high
levels of gelatinase A alone, with no associated synthesis of any
other members of the MMP supergene family, or of plasminogen
activator. Two independent strategies were developed to inhibit
gelatinase A synthesis. In the first, a 2297 bp fragment of the rat
72 kDa Type IV collagenase cDNA was subcloned in an antisense
orientation relative to the RSV LTR of the episomal vector
pRBK. MC were transfected with the antisense gelatinase A
construct, or with a control pRBK vector not containing an insert.
Step-wise increases in hygromycin concentration were used to
select for clones containing high levels of episomes. Multiple
hygromycin resistant clones were isolated and characterized for
the extent of gelatinase A synthetic suppression using a quantita-
tive tritiated gelatin assay, coupled with analytic gelatin zymogra-
phy. Decreases in secreted gelatinase A ranged from 37% to
greater than 95%, and were directly correlated with the degree of
episomal amplification determined by quantitative Hirt rescue of
episomal DNA.
The second strategy for inhibition of gelatinase A synthesis
utilized the retrovirally-mediated delivery of ribozymes targeted
to the gelatinase A mRNA. A retroviral transducing vector
pLNCX (gift of Dr. A.D. Miller) was modified to include a
hammerhead ribozyme cassette consisting of two overlapping
101-mer oligonucleotides, thereby creating the vector pLNCmx2.
The ribozyme cassette contained two hammerhead ribozyme
sequences designed to cleave GU C nucleotide motifs within the
sequences located at 963-985 and 1983-2007 of the rat gelatinase
A cDNA. To confirm the efficacy of the hammerhead ribozymes
for cleavage of the gelatinase A mRNA, synthetic gelatinase A
transcripts were incubated with each individual ribozyme tran-
script, as schematically shown in Figure 1 for the ribozyme active
at site 1983-2007. Incubation with the synthetic ribozyme in this
case shortens the synthetic MMP-2 transcript by the predicted
amount. Similar results were obtained for the other hammerhead
ribozyme construct.
A series of transfected and retrovirally infected clones were
evaluated. In those clones in which high level suppression of
gelatinase A synthesis occurred, the phenotype of the cells was
profoundly altered from the activated state and closely approxi-
mated that of quiescent cells in vivo. Thus, diminished gelatinase
A synthesis led to the loss of the smooth muscle a-actin activation
marker and major inhibition of cellular proliferation rates. The
decreases in cell proliferation rates could be directly correlated
with the degree of inhibition in gelatinase A synthesis. There was
1397
Hit]
1398 Turck et air Gelatinase A and MC growth
T7 MMP-2 transcript
Synthetic
ribozyme
transcript
Cut site
2150
C R
i4____ 1998
Fig. 1. Schematic of synthetic ribozyme cleavage
of target gelatinase A (MMP-2) transcripts. 32P-
labeled MMP-2 RNA transcripts were
generated from a T7 RNA polymerase site on a
pGEM 7zf vector containing the full length rat
MMP-2 eDNA. Incubation with the synthetic
ribozyme results in cleavage of the target
transcript, with resulting reduction in size from
2150 to 1998 bp (bottom panel).
a clear threshold level of gelatinase A synthesis (0.5 .rg/24hr/100
cell protein), below which a log-linear relation existed between
proliferation and suppression of gelatinase A synthesis. The
effects of gelatinase A synthetic suppression on the proliferative
capabilities of the cells was independent of the means utilized.
Virtually identical results were obtained with the episomally-
mediated antisense strategy as with the retrovirally-delivered
gelatinase A ribozymes.
Gelatinase A synthetic suppression also resulted in a dramatic
change in extracellular matrix protein synthetic patterns. Cultured
rat MC normally secrete interstitial collagens, with little or no
synthesis of Type IV collagens [6, 7]. Gelatinase A suppression,
either with the episomal system or the ribozymes, resulted in a
reversal of this synthetic pattern, which more closely resembles
the synthetic pattern in vivo.
Critical evidence against a nonspecific mechanism of phenotype
reversal was provided by gelatinase A reconstitution studies. For
these experiments, highly suppressed MC clones were exposed to
either purified gelatinase A, or the closely related gelatinase B,
and evaluated for the return of the typical inflammatory pheno-
type features. Addition of latent gelatinase A in concentrations
ranging from 0.1 n to 1 /M did not significantly affect the
behavior of the gelatinase A suppressed cells. In contrast, con-
centrations of 10 n and 100 n of active enzyme fully reconsti-
tuted the inflammatory phenotype, including induction of rapid
proliferation, extension of filopodial processes and expression of
smooth muscle a-actin. Further demonstration of the specificity of
the gelatinase A effect was provided by the fact that activated
gelatinase B, in concentrations as high as 10 !.tM, had no effect on
restitution of the inflammatory phenotype.
These purely in vitro observations on the pro-inflammatory
actions of gelatinase A for mesangial cells were extended to an in
vivo analysis that again compared the relative activities of purified
gelatinase A or gelatinase B. As noted above, in the normal
glomerulus the intrinsic mesangial cells are in a quiescent state
and do not synthesize gelatinase A, a condition which we at-
tempted to recapitulate in vitro with the antisense or ribozyme
strategies. For these experiments, the left kidneys of 200 gram
Sprague-Dawley rats were perfused with saline, followed by the
infusion of 1 /.LM solutions of gelatinase A or gelatinase B.
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Fig. 2. Active gelatinase A induces mesangial cell
proliferation in vivo. A. PCNA staining of
glomerulus perfused with active gelatinase B. B.
PCNA staining of glomerulus perfused with
active gelatinase A, demonstrating dark brown
positive staining (arrows). C. H&E staining of
glomerulus perfused wtih active gelatinase B. D.
H&E staining of glomerulus perfused with
active gelatinase A, demonstrating focal areas
of mesangial cell proliferation and expansion
(final magnifications: A—C, X400; D, X500)
Controls received saline alone. Each gelatinase was studied both
in the latent and in the active form. Following the gelatinase
enzyme infusions, renal artery perfusion was restored after a five
minute period. The animals were then sacrificed on the third day
and the renal cortical sections were examined by conventional
histology and by staining for the PCNA antigen proliferation
marker. The results of these experiments are summarized in
Figure 2. Infusion of saline alone had no effect on glomerular
morphology; infusion of gelatinase B, in either active or latent
form, had no effect on glomerular morphology or expression of
PCNA (Fig. 2A). In contrast, infusion of activated gelatinase A,
but not latent enzyme, led to a clear increase in glomerular PCNA
staining (Fig. 2B) and was accompanied by histologic evidence of
focal areas of mesangial cell proliferation (Fig. 2D). These
experiments directly confirm the significance of the in vitro studies
on gelatinase A suppression and demonstrate a direct role for
active gelatinase A for the induction of mesangial cell prolifera-
tion in vivo.
Summary
The studies detailed above have demonstrated the direct effect
of active gelatinase A on the induction of the inflammatory
glomerular mesangial cell phenotype, both in vitro and in vivo, but
leave the question of mechanisms unanswered. Some insights may
be provided by the fact that the closely related gelatinase B
enzyme was ineffective in these experiments. While very similar,
the two gelatinases do exhibit certain distinctions concerning
precise extracellular matrix protein substrate specificities. For
example, gelatinase B has a greater degree of activity against Type
IV and V collagens than does gelatinase A, while gelatinase A, but
not gelatinase B, can readily degrade laminin and fibronectin [8].
Proteolytically-derived fibronectin cleavage fragments have been
demonstrated to exhibit a number of cellular effects in other
systems, including induction of proliferation, migration and dif-
ferentiation [9]. Thus, it may be that the gelatinase A-mediated
pericellular release of biologically active fibronectin fragments
may provide the stimulus for the subsequent transition to the
inflammatory phenotype, a hypothesis that is currently undergo-
ing evaluation in our laboratory. Further insights into these
processes could facilitate the development of more specific ther-
apies of glomerular disease designed to target either the enzyme
activity or the biologically active peptides.
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